Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Wins Patent Suit over Elplat
November 1, 2016
- Shionogi Nets 12.2% Sales Rise on HIV Med Royalty Revenues
November 1, 2016
- Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
- Keytruda “Will Be Able to Contribute to 1st-Line Treatment” of NSCLC: MSD Official
November 1, 2016
- EA Pharma Files Japan NDA for Rectal-Foam Ulcerative Colitis Drug
October 31, 2016
- AZ to Commercialize Kyowa Kirin’s COPD Drug in Japan
October 31, 2016
- Astellas to Acquire German Cancer Biotech Ganymed
October 31, 2016
- Xtandi Re-Pricing Major Cause of Japan Sales Slump: Astellas President
October 31, 2016
- Astellas Sees Sales Drop, but Profits Grow on Lower Costs
October 31, 2016
- Takeda Ditches Flu Vaccine TAK-850 from Pipeline
October 31, 2016
- Takeda’s Half-Year Sales Slip on LLP Transfer, but Profits Zoom
October 31, 2016
- Kyowa Kirin Begins Global KRN23 PIII for Pediatric X-Linked Hypophosphatemia
October 28, 2016
- Sumitomo Dainippon’s Half-Year Revenue Dips on Price Cut, Currency
October 28, 2016
- Sumitomo Dainippon to Venture into Authorized Generic Arena
October 28, 2016
- Public “IP Platforms” Necessary for Startups: IPSN President
October 28, 2016
- Daiichi Sankyo Gets US Commercialization Rights on 2 Abuse-Deterrent Opioids
October 27, 2016
- Patritumab Joins I-SPY 2 Breast Cancer Program in US: Daiichi Sankyo
October 27, 2016
- Switching Over to Biologics Should Be Considered at Early Stage in Serious Cases of Psoriasis: Dermatologist
October 27, 2016
- AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
October 26, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…